Oruka Therapeutics (NASDAQ:ORKA) Director Kristine Ball Sells 18,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Kristine Ball sold 18,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $104.93, for a total transaction of $1,888,740.00. Following the completion of the transaction, the director directly owned 18,000 shares of the company’s stock, valued at $1,888,740. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA traded up $0.36 during trading on Friday, reaching $105.35. 679,678 shares of the company’s stock traded hands, compared to its average volume of 1,033,539. The stock has a market capitalization of $7.14 billion, a P/E ratio of -49.93 and a beta of -0.34. Oruka Therapeutics, Inc. has a 12 month low of $25.23 and a 12 month high of $115.51. The company has a 50 day moving average of $89.68 and a 200-day moving average of $72.36.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). Equities research analysts predict that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current fiscal year.

Key Headlines Impacting Oruka Therapeutics

Here are a few of the latest headlines about ORKA:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
• Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Wedbush restated an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 10th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $141.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at approximately $474,916,000. Remedium Capital Partners LLC raised its holdings in shares of Oruka Therapeutics by 0.9% during the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after buying an additional 13,247 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $130,968,000. Avidity Partners Management LP boosted its position in shares of Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares during the period. Finally, Voya Investment Management LLC boosted its position in shares of Oruka Therapeutics by 2.9% during the third quarter. Voya Investment Management LLC now owns 412,814 shares of the company’s stock worth $34,383,000 after buying an additional 11,665 shares during the period. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.